Full-size Left-side Hidden
Key references

1.. Boyd SR, Young S, Lightman S: Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol  2001; 46:209-233.

2.. Whitcup SM, Nussenblatt RB: Immunologic mechanisms of uveitis. New targets for immunomodulation. Arch Ophthalmol  1997; 115:520-525.

3.. Jabs DA, Nussenblatt RB, Rosenbaum JT: Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol  2005; 140:509-516.

5.. Chan CC, Wetzig RP, Palestine AG, et al: Immunohistopathology of ocular sarcoidosis. Report of a case and discussion of immunopathogenesis. Arch Ophthalmol  1987; 105:1398-1402.

20.. Martin TM, Rosenbaum JT: Genetics in uveitis. Int Ophthalmol Clin  2005; 45:15-30.

23.. Nussenblatt RB, Mittal KK, Ryan S, et al: Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol  1982; 94:147-158.

32.. Li Z, Liu B, Maminishkis A, et al: Gene expression profiling of autoimmune noninfectious uveitis disease. J Immunol  2008; 181:5147-5157.

34.. Miceli-Richard C, Lesage S, Rybojad M, et al: CARD15 mutations in Blau syndrome. Nat Genet  2001; 29:19-20.

40.. Sugita S, Takase H, Taguchi C, et al: Ocular infiltrating CD4+ T cells from patients with Vogt–Koyanagi–Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci  2006; 47:2547-2554.

44.. Amadi-Obi A, Yu CR, Liu X, et al: TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med  2007; 13:711-718.

47.. Silver PB, Agarwal RK, Su SB, et al: Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J Immunol  2007; 179:5146-5158.

55.. Foxman EF, Zhang M, Hurst SD, et al: Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol  2002; 168:2483-2492.

70.. Fine HF, Baffi J, Reed GF, et al: Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol  2001; 132:794-796.

86.. Jabs DA, Rosenbaum JT, Foster CS, et al: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol  2000; 130:492-513.

94.. Galor A, Perez VL, Hammel JP, et al: Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology  2006; 113:2317-2323.